Reported 3 days ago
Neumora Therapeutics Inc. experienced a significant drop in share value, plummeting by as much as 83%, after their experimental drug navacaprant failed to demonstrate efficacy in treating major depressive disorder in a final-stage study. Despite previous optimism from analysts regarding the drug's potential, the trial's results have cast doubt on its future, although Neumora continues to pursue additional trials and develop other brain disorder treatments.
Source: YAHOO